Search for stocks /

PCBL Chemical:₹1,846 Cr Revenue. ₹4.66 Cr PAT. 95% Profit Collapse. This Quarter is “The Turning Point”

PCBL Chemical Q3 FY26 | EduInvesting
Q3 FY26 Results · December Quarter Reporting (Oct–Dec 2025)

PCBL Chemical:
₹1,846 Cr Revenue. ₹4.66 Cr PAT. 95% Profit Collapse.
This Quarter is “The Turning Point”

India’s largest carbon black maker just posted its worst quarter in years. CEO says this is “the turning point.” CFO says geopolitical tariffs and crude inventory cycles destroyed margins. Everyone’s hedging. Nobody’s celebrating.

Market Cap₹10,224 Cr
CMP₹260
P/E Ratio39.3x
Div Yield2.30%
ROCE11.8%

The Carbon Black Maker That Took One On The Chin

  • 52-Week High / Low₹444 / ₹254
  • Q3 FY26 Revenue₹1,846 Cr
  • Q3 FY26 PAT₹4.66 Cr
  • Q3 FY26 EPS₹0.05
  • Annualised EPS (Q3×4)₹0.20
  • Book Value₹98.4
  • Price to Book2.67x
  • Dividend Yield2.30%
  • Debt / Equity1.36x
  • Return (1-Yr)-27.0%
The Situation: PCBL crushed Q3 FY26 with ₹1,846 crore revenue (-8.2% YoY), but PAT tanked 95% to ₹4.66 crore due to export headwinds, tariff pressure, crude inventory cycles, and subdued carbon black realizations. The company’s Aquapharm acquisition (₹3,800 crore in Jan 2024) remains a drag, posting ₹35 crore EBITDA in Q3. Stock has halved from ₹444 to ₹260 in 12 months. Yet management claims “this quarter is the turning point” and launched a ₹200 crore cost-out program. Either they know something, or they’re practicing heroic optimism.

How To Disappoint Your Shareholder Base In One Quarter

PCBL Chemical Limited is India’s largest carbon black producer and the world’s 7th largest, with 790,000 MTPA installed capacity across five plants. It also bought Aquapharm Chemicals (specialty phosphonates, water treatment, oil & gas solutions) for ₹3,800 crore in Jan 2024 via subsidiary Advaya Chemical. The plan was diversification. The reality? Aquapharm is struggling harder than a monsoon duck.

Q3 FY26 became a masterclass in how commodity cycles, geopolitical tariffs, and crude oil inventory adjustments team up to destroy quarterly earnings. Carbon black realisations—the price per ton—dropped significantly due to supply overhang and dumping. Aquapharm’s Oil & Gas segment collapsed (-23% YoY) because U.S. rig counts and fracking spreads went sideways. And the U.S. tariff on Indian carbon black jumped from ~10% (with offsets) to 18% effective, putting customers in a holding pattern.

Management’s full-year guidance before Q3? “Growing volumes, improving margins.” Q3 reality? Volumes up slightly YoY at 9M, but margins in free fall. PAT down 95% in a single quarter. That’s not a guidance miss. That’s a guidance demolition.

Yet in the concall, the new MD (appointed Nov 2025 after the previous MD’s resignation) said—and I quote—”this quarter is the turning point. You should expect better performance going quarter-to-quarter.” Whether that’s insight or hope trafficking, read on.

Concall Reality Check (Feb 2026): CFO clarified that Q3 weakness was “predominantly exports” (US/EU tariff chaos) and “calendar-year destocking” by international customers in December. Domestic demand “held up.” Industry utilization: ~75% vs normal ~80%. Translation: industry capacity is too much for current demand. Pricing power returns when mills fill up.

We Make The Stuff That Makes Tyres Actually Work

Carbon black is a fine powder made from partial combustion of oil. It’s the reinforcing agent in tyres—basically, without it, your tyre would tear after 500 km. It’s also in inks, coatings, plastics, batteries, and now—cutting-edge—data centre cooling fluids (via Nanovace, the battery materials JV).

PCBL has 678,000 MTPA rubber black capacity and 112,000 MTPA specialty black capacity (the higher-margin stuff). In Q3, they sold 141,271 MT: 81,219 MT tyres, 43,352 MT performance chemicals, 16,700 MT specialty. Domestic demand: resilient. Export volume: brutalised by US tariffs and EU uncertainty.

Aquapharm, acquired Jan 2024, makes phosphonates (used in detergents, water treatment, oil & gas). It contributed ₹327 crore revenue in Q3 but only ₹35 crore EBITDA—a 10.7% margin. For context, PCBL’s standalone carbon black margins used to hover 16%+. Aquapharm is bringing down group profitability while everyone waits for scale and new markets (Saudi water authorities LOI received for anti-scalant—yay, baby steps).

Carbon Black Share~78%Of Group Revenue
Aquapharm Share~22%Of Group Revenue
Export Mix~37%Standalone PCBL
The Tariff Wall: U.S. tariff on PCBL’s exports jumped from ~4% effective (under old 10% nominal + CBFS offsets) to ~8-9% effective (under new 18% nominal). That’s 100-200 bps of margin gone. Customers were “more worried about tariff instability than the absolute rate,” per management—which is just fancy speak for “we lost customers temporarily while they renegotiated.” Volume recapture may take months.
💬 Real talk: Would you invest in a company’s acquisition that’s eating 22% of group revenue but delivering 7% margins instead of 16%? Or would you wait for the turnaround?

Q3 FY26: When Margins Go To Die

Continue reading with a premium membership.
Become a member
error: Content is protected !!